Bion Labs
São Paulo, Brazil· Est.
Peptide‑only CMC risk‑governance consultancy de‑risking early‑stage biotech manufacturing decisions.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
Peptide‑only CMC risk‑governance consultancy de‑risking early‑stage biotech manufacturing decisions.
Peptide therapeutics
Technology Platform
Risk‑governance framework using ICH Q9, FMEA RPN scoring, decision architecture mapping, and CDMO capability envelope assessment for peptide CMC.
Opportunities
Capitalizing on the growing peptide therapeutics market by offering rapid, unbiased CMC risk assessment and CDMO qualification services to early‑stage biotech firms.
Risk Factors
Limited brand visibility and reliance on a niche client base; competition from larger CMC consultancies may erode market share.
Competitive Landscape
Competes with broad‑scope CMC consultancies but differentiates through a peptide‑only focus, fast turnaround, and conflict‑free advisory model.